- About us
- Join Putnam
With our life science consulting expertise spanning across commercial, value, pricing, and access, and medical and scientific affairs, inclusive of various sub-offerings, and core centers of excellence, we’re equipped with the capabilities and knowledge to support your next big challenge.
As a leading provider of life science consulting and scientific and strategic advisory services, we serve a broad variety of clients, including all of the top 20 global biopharmaceutical organizations, small and mid-size biopharmas, emerging biotech companies, and leading private equity and venture capital firms.
We provide commercial advisory solutions across the product development and commercialization lifecycle to ensure the greatest clinical impact to patients.
We provide evidence generation, HTA navigation, pricing and access strategy, payer and channel contracting, and distribution strategy to drive patient access and commercial success.
We provide service global evidence identification and articulation, clinical development and lifecycle strategy, evidence generation strategy, and stakeholder engagement.
At Putnam, our global team of rigorously trained and highly engaged scientists and strategists dig deep to solve your
most complex challenges and advance your innovations.
Our focus on every project is the same: to deliver immense impact and exceptional value through world-class advisory solutions.
We partner with client teams to design solutions with a strategic goal in mind, asking the right questions to find answers that lead to impact.
We produce analysis, insights, and recommendations that are executive-team ready to drive critical business decisions forward.
We deliver scientific excellence and innovation to build value and support access.
We invest our time and energy in the long-term success of clients, supporting their needs inside and outside of engagements.
We get the job done with rigor and insight the first time, standing up experienced teams that can efficiently and accurately execute on needs.
Get the latest insights and perspectives from our experts.
US and EU regulatory agencies provided the client with new guidance on generating supportive evidence for the proposed launch indication and future.
The client with a focus on developing pipeline asset for KRAS G12C segment sought granular insights for competitive edge in treatment sequencing.
We worked with our client to develop a forward-looking early development program evaluation tool that identifies key inflection points...